SAGE-718-matching placebo

DRUG2 trials

Sponsors

Supernus Pharmaceuticals, Inc.

Conditions

Alzheimer's DiseaseCognitive DysfunctionMild Cognitive ImpairmentMild DementiaParkinson Disease

Phase 2

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

CompletedNCT05318937

Supernus Pharmaceuticals, Inc.Cognitive Dysfunction, Parkinson Disease

Start: 2022-06-06End: 2024-02-23Updated: 2025-09-12

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

CompletedNCT05619692

Supernus Pharmaceuticals, Inc.Alzheimer's Disease, Mild Cognitive Impairment, Mild Dementia

Start: 2022-11-29End: 2024-07-09Updated: 2025-09-15

Related Papers

The Phase 2, Randomized, Placebo-controlled PRECEDENT Trial of SAGE-718 in Patients With Parkinson's Disease Cognitive Impairment: Clinical Trial in Progress (P2-11.005)

Neurology2023-04-25